Ascletis files two FDA INDs for once-monthly obesity drugs targeting amylin, GLP-1R, and GIPR
July 06, 2026 | 14:23
Ascletis submitted two IND applications to the US FDA for obesity treatments: ASC36, a once-monthly peptide amylin receptor agonist, and ASC36_35 FDC, a potentially first-in-class co-formulation hitting three validated targets — amylin receptor, GLP-1R, and GIPR — in a single monthly injection.
Latest News
Mobile Version